Kantaro Biosciences, a joint venture between the Mount Sinai Health System and RenalytixAI (RNLX), has received Emergency Use Authorization from the FDA for COVID-SeroKlir, its semi-quantitative SARS-CoV-2 IgG antibody test kit. COVID-SeroKlir has showed 98.8% sensitivity and 99.6% specificity for detecting SARS-CoV-2 specific IgG antibodies against two virus antigens. Kantaro noted that, unlike other antibody tests, COVID-SeroKlir determines the presence and precise level of IgG antibodies.
Through a commercial partnership with Bio-Techne Corp. (TECH), the test kits are being manufactured at scale with a capacity of up to 10 million tests per month.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.